GB201020671D0 - Passive immunotherapy - Google Patents
Passive immunotherapyInfo
- Publication number
- GB201020671D0 GB201020671D0 GBGB1020671.2A GB201020671A GB201020671D0 GB 201020671 D0 GB201020671 D0 GB 201020671D0 GB 201020671 A GB201020671 A GB 201020671A GB 201020671 D0 GB201020671 D0 GB 201020671D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- passive immunotherapy
- antibodies
- tuberculosis
- exclusively
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to antibodies to Mycobacterium tuberculosis, and to methods, compositions and cells associated with such antibodies. Such antibodies are useful of the treatment of tuberculosis, particularly but not exclusively through passive immunotherapy.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1020671.2A GB201020671D0 (en) | 2010-12-07 | 2010-12-07 | Passive immunotherapy |
PCT/GB2011/052404 WO2012076868A1 (en) | 2010-12-07 | 2011-12-06 | Antibodies to mycobacteria |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1020671.2A GB201020671D0 (en) | 2010-12-07 | 2010-12-07 | Passive immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201020671D0 true GB201020671D0 (en) | 2011-01-19 |
Family
ID=43531554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1020671.2A Ceased GB201020671D0 (en) | 2010-12-07 | 2010-12-07 | Passive immunotherapy |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201020671D0 (en) |
WO (1) | WO2012076868A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US10414819B2 (en) | 2013-08-30 | 2019-09-17 | Longhorn Vaccines And Diagnostics, Llc | Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance |
US9821047B2 (en) | 2013-08-30 | 2017-11-21 | Longhorn Vaccines And Diagnostics, Llc | Enhancing immunity to tuberculosis |
US10370437B2 (en) | 2013-08-30 | 2019-08-06 | Longhorn Vaccines And Diagnostics, Llc | Antibodies that modulate immunity to drug resistant and latent MTB infections |
WO2022034513A1 (en) * | 2020-08-12 | 2022-02-17 | Università Cattolica del Sacro Cuore | Composition for use in the treatment of respiratory infection caused by coronavirus |
-
2010
- 2010-12-07 GB GBGB1020671.2A patent/GB201020671D0/en not_active Ceased
-
2011
- 2011-12-06 WO PCT/GB2011/052404 patent/WO2012076868A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012076868A1 (en) | 2012-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX340831B (en) | Pesticidal compositions. | |
MX2013001473A (en) | Antibodies against il-18r1 and uses thereof. | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
MX360499B (en) | Microbial strains, compositions, and methods for increasing available phosphate for plants. | |
MX2013001045A (en) | Liver organoid, uses thereof and culture method for obtaining them. | |
MX2013011479A (en) | Anti-fgfr4 antibodies and methods of use. | |
MX336001B (en) | Anti-axl antibodies and methods of use. | |
MX345909B (en) | Anti-fgfr3 antibodies and methods using same. | |
MX2012008941A (en) | Organo-metallic frameworks derived from carbenophilic metals and method of making same. | |
MY181898A (en) | Heterocyclic compounds and uses thereof | |
MX2013008390A (en) | Preparation of metal-triazolate frameworks. | |
GB2492305A (en) | Polymers of benzodithiophene and their use as organic semiconductors | |
MX2014002053A (en) | Anti-mcsp antibodies. | |
MX2014004022A (en) | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE. | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
TN2012000366A1 (en) | Anticoagulant antidotes | |
AU2014233478A8 (en) | Anti-CD25 antibodies and their uses | |
CA2866116C (en) | Expansion of alloantigen-reactive regulatory t cells | |
MX2013012184A (en) | In-situ gel forming compositions. | |
MX2012011829A (en) | Anti-polyubiquitin antibodies and methods of use. | |
WO2011133504A3 (en) | Nanozymes, methods of making nanozymes, and methods of using nanozymes | |
MX2014014376A (en) | Anti-biotin antibodies and methods of use. | |
MX337203B (en) | Novel jnk inhibitor molecules. | |
MX2015012563A (en) | Anti-cd25 antibodies and their uses. | |
MX2012007379A (en) | Anti-bv8 antibodies and uses thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |